MovDisordV3, Main, Exploration, bibRecord, 000A81

Caffeine Consumption and Risk of Dyskinesia in CALM-PD

Identifieur interne : 000A81 ( Main/Exploration ); précédent : 000A80; suivant : 000A82

Caffeine Consumption and Risk of Dyskinesia in CALM-PD

Auteurs : Anne-Marie A. Wills [États-Unis] ; Shirley Eberly [États-Unis] ; Marsha Tennis [États-Unis] ; Anthony E. Lang ; Susan Messing [États-Unis] ; Daniel Togasaki [États-Unis] ; Caroline M. Tanner [États-Unis] ; Cornelia Kamp [États-Unis] ; Jiang-Fan Chen [États-Unis] ; David Oakes [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Michael A. Schwarzschild [États-Unis]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2013.

RBID : PMC:3608707

English descriptors

KwdEn :
- Adenosine A2 Receptor Antagonists (administration & dosage), Adenosine A2 Receptor Antagonists (metabolism), Aged, Antiparkinson Agents (adverse effects), Benzothiazoles (adverse effects), Caffeine (administration & dosage), Caffeine (metabolism), Cohort Studies, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (prevention & control), Female, Humans, Kaplan-Meier Estimate, Levodopa (adverse effects), Male, Middle Aged, Parkinson Disease (drug therapy), Proportional Hazards Models, Retrospective Studies, Risk.
MESH :
- chemical , administration & dosage : Adenosine A2 Receptor Antagonists, Caffeine.
- chemical , adverse effects : Antiparkinson Agents, Benzothiazoles, Levodopa.
- chemical , metabolism : Adenosine A2 Receptor Antagonists, Caffeine.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Aged, Cohort Studies, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk.

Abstract

Background

Adenosine A_2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia.

Methods

We examined the association between self-reported intake of the A_2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson’s Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson’s severity, site, and initial treatment with pramipexole or levodopa.

Results

For subjects who consumed > 12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% confidence interval, 0.37–1.01) compared to subjects who consumed < 4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (C.I. 0.46–1.15) (test for trend, p = 0.05).

Conclusions

These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608707

DOI: 10.1002/mds.25319
PubMed: 23339054
PubMed Central: 3608707

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Caffeine Consumption and Risk of Dyskinesia in CALM-PD</title>
<author><name sortKey="Wills, Anne Marie A" sort="Wills, Anne Marie A" uniqKey="Wills A" first="Anne-Marie A." last="Wills">Anne-Marie A. Wills</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tennis, Marsha" sort="Tennis, Marsha" uniqKey="Tennis M" first="Marsha" last="Tennis">Marsha Tennis</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><nlm:aff id="A3">Department of Medicine, Division of Neurology, University of Toronto, and the Edmond J. Safra Program in Parkinson’s Disease, University Health Network, Toronto ON</nlm:aff>
<wicri:noCountry code="subfield">Toronto ON</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Messing, Susan" sort="Messing, Susan" uniqKey="Messing S" first="Susan" last="Messing">Susan Messing</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Togasaki, Daniel" sort="Togasaki, Daniel" uniqKey="Togasaki D" first="Daniel" last="Togasaki">Daniel Togasaki</name>
<affiliation wicri:level="4"><nlm:aff id="A4">Department of Neurology, University of Southern California, Los Angeles, CA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Southern California, Los Angeles, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Los Angeles</settlement>
</placeName>
<orgName type="university">Université de Californie du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Parkinson’s Institute, Sunnyvale, CA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Parkinson’s Institute, Sunnyvale</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Jiang Fan" sort="Chen, Jiang Fan" uniqKey="Chen J" first="Jiang-Fan" last="Chen">Jiang-Fan Chen</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Molecular Neuropharmacology Laboratory, Boston University, Boston, MA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Molecular Neuropharmacology Laboratory, Boston University, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">23339054</idno>
<idno type="pmc">3608707</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608707</idno>
<idno type="RBID">PMC:3608707</idno>
<idno type="doi">10.1002/mds.25319</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000307</idno>
<idno type="wicri:Area/Pmc/Curation">000307</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000136</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000B02</idno>
<idno type="wicri:Area/PubMed/Curation">000B02</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A92</idno>
<idno type="wicri:Area/Ncbi/Merge">003979</idno>
<idno type="wicri:Area/Ncbi/Curation">003979</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003979</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Wills A:caffeine:consumption:and</idno>
<idno type="wicri:Area/Main/Merge">000A81</idno>
<idno type="wicri:Area/Main/Curation">000A81</idno>
<idno type="wicri:Area/Main/Exploration">000A81</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Caffeine Consumption and Risk of Dyskinesia in CALM-PD</title>
<author><name sortKey="Wills, Anne Marie A" sort="Wills, Anne Marie A" uniqKey="Wills A" first="Anne-Marie A." last="Wills">Anne-Marie A. Wills</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tennis, Marsha" sort="Tennis, Marsha" uniqKey="Tennis M" first="Marsha" last="Tennis">Marsha Tennis</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><nlm:aff id="A3">Department of Medicine, Division of Neurology, University of Toronto, and the Edmond J. Safra Program in Parkinson’s Disease, University Health Network, Toronto ON</nlm:aff>
<wicri:noCountry code="subfield">Toronto ON</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Messing, Susan" sort="Messing, Susan" uniqKey="Messing S" first="Susan" last="Messing">Susan Messing</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Togasaki, Daniel" sort="Togasaki, Daniel" uniqKey="Togasaki D" first="Daniel" last="Togasaki">Daniel Togasaki</name>
<affiliation wicri:level="4"><nlm:aff id="A4">Department of Neurology, University of Southern California, Los Angeles, CA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Southern California, Los Angeles, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
<settlement type="city">Los Angeles</settlement>
</placeName>
<orgName type="university">Université de Californie du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<affiliation wicri:level="2"><nlm:aff id="A5">Parkinson’s Institute, Sunnyvale, CA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Parkinson’s Institute, Sunnyvale</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Jiang Fan" sort="Chen, Jiang Fan" uniqKey="Chen J" first="Jiang-Fan" last="Chen">Jiang-Fan Chen</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Molecular Neuropharmacology Laboratory, Boston University, Boston, MA, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Molecular Neuropharmacology Laboratory, Boston University, Boston, MA</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<affiliation wicri:level="2"><nlm:aff id="A2">Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A6">Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester, Rochester, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name>
<affiliation wicri:level="2"><nlm:aff id="A1">Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine A2 Receptor Antagonists (administration & dosage)</term>
<term>Adenosine A2 Receptor Antagonists (metabolism)</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Benzothiazoles (adverse effects)</term>
<term>Caffeine (administration & dosage)</term>
<term>Caffeine (metabolism)</term>
<term>Cohort Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Proportional Hazards Models</term>
<term>Retrospective Studies</term>
<term>Risk</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine A2 Receptor Antagonists</term>
<term>Caffeine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzothiazoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenosine A2 Receptor Antagonists</term>
<term>Caffeine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cohort Studies</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Proportional Hazards Models</term>
<term>Retrospective Studies</term>
<term>Risk</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P1">Adenosine A<sub>2A</sub>
 receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">We examined the association between self-reported intake of the A<sub>2A</sub>
 receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson’s Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson’s severity, site, and initial treatment with pramipexole or levodopa.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">For subjects who consumed > 12 ounces of coffee/day, the adjusted hazard ratio for the development of dyskinesia was 0.61 (95% confidence interval, 0.37–1.01) compared to subjects who consumed < 4 ounces/day. For subjects who consumed between 4 and 12 ounces/day, the adjusted hazard ratio was 0.73 (C.I. 0.46–1.15) (test for trend, p = 0.05).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">These results support the possibility that caffeine may reduce the likelihood of developing dyskinesia.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Massachusetts</li>
<li>État de New York</li>
</region>
<settlement><li>Los Angeles</li>
</settlement>
<orgName><li>Université de Californie du Sud</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Wills, Anne Marie A" sort="Wills, Anne Marie A" uniqKey="Wills A" first="Anne-Marie A." last="Wills">Anne-Marie A. Wills</name>
</region>
<name sortKey="Chen, Jiang Fan" sort="Chen, Jiang Fan" uniqKey="Chen J" first="Jiang-Fan" last="Chen">Jiang-Fan Chen</name>
<name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<name sortKey="Kamp, Cornelia" sort="Kamp, Cornelia" uniqKey="Kamp C" first="Cornelia" last="Kamp">Cornelia Kamp</name>
<name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael P." last="Mcdermott">Michael P. Mcdermott</name>
<name sortKey="Messing, Susan" sort="Messing, Susan" uniqKey="Messing S" first="Susan" last="Messing">Susan Messing</name>
<name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name>
<name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name>
<name sortKey="Tennis, Marsha" sort="Tennis, Marsha" uniqKey="Tennis M" first="Marsha" last="Tennis">Marsha Tennis</name>
<name sortKey="Togasaki, Daniel" sort="Togasaki, Daniel" uniqKey="Togasaki D" first="Daniel" last="Togasaki">Daniel Togasaki</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A81 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A81 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3608707
   |texte=   Caffeine Consumption and Risk of Dyskinesia in CALM-PD
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23339054" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Caffeine Consumption and Risk of Dyskinesia in CALM-PD

Caffeine Consumption and Risk of Dyskinesia in CALM-PD

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.